Prelude Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,149
| Closed | -$208K | – | 1289 |
|
|
2024
Q1 | $208K | Sell |
4,149
-6,851
| -62% | -$344K | 0.01% | 977 |
|
|
2023
Q4 | $664K | Buy |
11,000
+4,600
| +72% | +$278K | 0.04% | 346 |
|
|
2023
Q3 | $365K | Buy |
+6,400
| New | +$365K | 0.02% | 478 |
|
|
2022
Q1 | – | Sell |
-50,000
| Closed | -$495K | – | 1753 |
|
|
2021
Q4 | $495K | Hold |
50,000
| – | – | 0.01% | 791 |
|
|
2021
Q3 | $498K | Hold |
50,000
| – | – | 0.01% | 668 |
|
|
2021
Q2 | $518K | Buy |
+50,000
| New | +$518K | 0.02% | 728 |
|